Redhill Biophrma ADR (RDHL)

$1.02 -0.01 (-0.97%)
Market Cap 5.35M
Revenue (ttm) 290,000.00
Net Income (ttm) -430,000.00
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -148.28%
Debt to Equity Ratio 0.00
Volume 17,000
Avg Vol 38,904
Day's Range N/A - N/A
Shares Out 5.19M
Stochastic %K 52%
Beta 5.05
Analysts Strong Buy
Price Target $40.00

Company Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear ra...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 972 3 541 3131
Fax: 972 3 541 3144
Address:
21 Ha’arba’a Street, Tel Aviv-Yafo, Israel
BillionerOfKing
BillionerOfKing Apr. 30 at 7:41 PM
$RDHL Current Stock Price: $1.09
0 · Reply
Popajay
Popajay Apr. 30 at 1:53 PM
$RDHL RALEIGH, N.C. and TEL AVIV, Israel, April 30, 2026 /PRNewswire/ -- RedHill Biopharma Ltd.(RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced new in vitro testing results demonstrating RHB-204's comparability to RHB-104 in Mycobacterium avium subspecies paratuberculosis (MAP) killing efficacy. Oral RHB-204 is a next-generation optimized formulation of RedHill's RHB-104, designed for enhanced tolerability, safety profile and patient adherence, that employs a groundbreaking MAP-targeted therapeutic approach to the treatment of Crohn's disease (CD).
0 · Reply
Popajay
Popajay Apr. 30 at 1:52 PM
$RDHL Expected transferal of RHB-104's FDA pediatric orphan drug designation to RHB-204, potential for breakthrough therapy designation, fast track designation, additional regulatory exclusivity and priority review voucher. RHB-204 is patent protected through 2041, granted FDA Fast Track and Orphan Drug Designation, QIDP Designation under the GAIN Act (extending US market exclusivity to a potential total of 12 years) and EU Orphan Designation (eligibility for 10 years EU market exclusivity) for NTM disease caused by MAC5 The multibillion-dollar CD market is expected to grow from $13.6 billion in 2024 to over $19 billion in 2033 in key markets,6 presenting a significant opportunity for new FDA-approved therapies
0 · Reply
Popajay
Popajay Apr. 30 at 1:50 PM
$RDHL New RHB-204 in vitro data, from both spot and phage assays, demonstrated comparable MAP killing to RHB-1044. Importantly, MAP killing efficacy was achieved with lower doses of two of the active ingredients compared to RHB-104, indicative of potential for reduced toxicity and side effects Based on the FDA guidance on path to approval, RedHill's novel Phase 2 RHB-204 study is designed to be the first-ever adequately controlled clinical study in a specifically defined MAP-positive CD patient population - a potentially paradigm changing approach to treatment of Crohn's disease. With discussions ongoing and grant application submitted, funding for this program is planned to be non-dilutive
0 · Reply
Popajay
Popajay Apr. 30 at 1:50 PM
$RDHL RHB-2041 is a next-generation optimized formulation of RedHill's oral RHB-1042, designed for enhanced tolerability, safety profile and patient adherence, that employs a groundbreaking Mycobacterium avium subspecies paratuberculosis (MAP)-targeted therapeutic approach for Crohn's disease (CD) In its positive Phase 3 study, RHB-104 met the primary and key secondary endpoints with statistical significance, showing RHB-104 plus standard of care (SoC) to be 64% more effective than SoC alone, in treating CD compared to the placebo (standard of care only) group (p = 0.0048)3
0 · Reply
DARKP00L
DARKP00L Apr. 30 at 11:23 AM
$RDHL 07:12 on Apr. 30 2026 Redhill Biopharma Announces New In Vitro Testing Results Demonstrating RHB-204's Comparability To RHB-104 In Mycobacterium Avium Subspecies Paratuberculosis Killing Efficacy #tradeideas
0 · Reply
Patrick2343
Patrick2343 Apr. 27 at 5:03 PM
$RDHL RedHill is actively pursuing funding opportunities and partnerships to advance this potential paradigm-shifting treatment. - aka we will dilute.
0 · Reply
Balmus
Balmus Apr. 27 at 12:40 PM
$RDHL Going Concern Our consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. During the year ended December 31, 2025, our net cash used in operating activities was $9.7 million leaving a cash balance of $4.1 million. Because we do not have sufficient resources to fund our operations for the next twelve months from the date of this filing, management has substantial doubt of our ability to continue as a going concern. See "- B. Operating Results - Going Concern". https://www.marketscreener.com/news/redhill-biopharma-annual-report-for-fiscal-year-ending-2025-12-31-form-20-f-ce7f59dcd18ef223
1 · Reply
SavageJohnny
SavageJohnny Apr. 26 at 5:27 AM
$RDHL Nasdaq Compliance Issues: On April 14, 2026, the company received a formal notice from Nasdaq because its share price had closed below $1.00 for 30 consecutive business days (Feb 20 – April 2). RedHill has until October 5, 2026, to regain compliance by having the stock close at $1.00 or higher for at least 10 consecutive business days
0 · Reply
Patrick2343
Patrick2343 Apr. 23 at 7:28 PM
$RDHL I had bought some shares in the 70's sold them all today I have learned how they pump and dump this thing. When it runs up its best to unload asap before the dump it with an offering.
0 · Reply
Latest News on RDHL
RedHill Biopharma’s RHB-204 shows efficacy in Crohn’s Disease

2026-04-30T11:52:17.000Z - 13 days ago

RedHill Biopharma’s RHB-204 shows efficacy in Crohn’s Disease

RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease

Apr 30, 2026, 7:00 AM EDT - 13 days ago

RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease

CPIX

RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights

Apr 27, 2026, 8:00 AM EDT - 16 days ago

RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights

CPIX

RedHill Biopharma announces presentation of preclinical data on opaganib at AACR

2026-04-22T12:40:23.000Z - 21 days ago

RedHill Biopharma announces presentation of preclinical data on opaganib at AACR

RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026

Apr 22, 2026, 8:00 AM EDT - 21 days ago

RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026

CPIX

RedHill Biopharma announces full sales and operational launch of Talicia

2026-02-25T12:17:19.000Z - 2 months ago

RedHill Biopharma announces full sales and operational launch of Talicia

CPIX

Joint U.S. Commercialization of RedHill's Talicia® Commences

Feb 25, 2026, 7:00 AM EST - 2 months ago

Joint U.S. Commercialization of RedHill's Talicia® Commences

CPIX

RedHill Biopharma announces development progress for RHB-102

2026-01-05T12:05:42.000Z - 4 months ago

RedHill Biopharma announces development progress for RHB-102

RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects

Jan 5, 2026, 7:00 AM EST - 4 months ago

RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects

RedHill Biopharma announces in vivo results on opaganib, venetoclax

2025-12-15T12:10:59.000Z - 5 months ago

RedHill Biopharma announces in vivo results on opaganib, venetoclax

RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells

Dec 15, 2025, 7:00 AM EST - 5 months ago

RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells

RedHill Biopharma regains compliance with Nasdaq equity requirement

2025-12-01T12:11:10.000Z - 5 months ago

RedHill Biopharma regains compliance with Nasdaq equity requirement

RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement

Dec 1, 2025, 7:00 AM EST - 5 months ago

RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement

RedHill says $10.5M New York Supreme Court judgment now final for enforcement

2025-11-04T17:05:24.000Z - 6 months ago

RedHill says $10.5M New York Supreme Court judgment now final for enforcement

RedHill Biopharma announces $10.5M New York Supreme Court judgment win

2025-11-04T14:35:55.000Z - 6 months ago

RedHill Biopharma announces $10.5M New York Supreme Court judgment win

RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement

Nov 4, 2025, 9:30 AM EST - 6 months ago

RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement

RedHill Biopharma Receives Nasdaq Staff Determination Notification

Oct 22, 2025, 4:50 PM EDT - 7 months ago

RedHill Biopharma Receives Nasdaq Staff Determination Notification

RedHill Biopharma signs strategic partnership with Cumberland

2025-10-20T13:05:16.000Z - 7 months ago

RedHill Biopharma signs strategic partnership with Cumberland

CPIX

CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

Oct 20, 2025, 9:05 AM EDT - 7 months ago

CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

CPIX

RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia®

Oct 6, 2025, 8:00 AM EDT - 7 months ago

RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia®

RedHill Biopharma wins New York Supreme Court appeal

2025-09-29T11:10:10.000Z - 8 months ago

RedHill Biopharma wins New York Supreme Court appeal

RedHill Biopharma wins New York Supreme Court appeal

2025-09-29T11:05:11.000Z - 8 months ago

RedHill Biopharma wins New York Supreme Court appeal

RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo

Sep 29, 2025, 7:00 AM EDT - 8 months ago

RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo

RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights

Sep 5, 2025, 7:00 AM EDT - 8 months ago

RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights

RedHill awarded $1.82M in legal costs and expenses in action against Kukbo

2025-08-20T13:10:09.000Z - 9 months ago

RedHill awarded $1.82M in legal costs and expenses in action against Kukbo

RedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment Win

Aug 20, 2025, 9:00 AM EDT - 9 months ago

RedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment Win

RedHill Biopharma receives Talicia licensing payments totaling $1.1M

2025-08-18T13:05:11.000Z - 9 months ago

RedHill Biopharma receives Talicia licensing payments totaling $1.1M

RedHill Received Talicia® Licensing Payments Totaling $1.1 Million

Aug 18, 2025, 9:00 AM EDT - 9 months ago

RedHill Received Talicia® Licensing Payments Totaling $1.1 Million

RedHill Biopharma receives positive FDA feedback for RHB-204 in Crohn’s Disease

2025-07-21T13:12:17.000Z - 10 months ago

RedHill Biopharma receives positive FDA feedback for RHB-204 in Crohn’s Disease

RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease

Jul 21, 2025, 9:00 AM EDT - 10 months ago

RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease

RedHill initiates recruitment for expanded Phase 2 opaganib/darolutamide study

2025-07-01T16:10:28.000Z - 11 months ago

RedHill initiates recruitment for expanded Phase 2 opaganib/darolutamide study

RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer

Jul 1, 2025, 12:00 PM EDT - 11 months ago

RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer

RedHill Biopharma secures Kukbo asset freeze after $8.25M favorable court ruling

2025-05-13T11:11:21.000Z - 1 year ago

RedHill Biopharma secures Kukbo asset freeze after $8.25M favorable court ruling

RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win

May 13, 2025, 7:00 AM EDT - 1 year ago

RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win

RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress

May 2, 2025, 7:00 AM EDT - 1 year ago

RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress

RedHill Biopharma granted Chinese patent application for COVID-19 treatment

2025-04-28T11:16:04.000Z - 1 year ago

RedHill Biopharma granted Chinese patent application for COVID-19 treatment

RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107

Apr 28, 2025, 7:03 AM EDT - 1 year ago

RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107

RedHill Biopharma receives non-compliance letter from Nasdaq

2025-04-17T20:06:13.000Z - 1 year ago

RedHill Biopharma receives non-compliance letter from Nasdaq

RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

Apr 17, 2025, 4:01 PM EDT - 1 year ago

RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

RedHill Biopharma announces publication in journal on Opaganib

2025-04-16T11:13:28.000Z - 1 year ago

RedHill Biopharma announces publication in journal on Opaganib

RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption

Apr 16, 2025, 7:00 AM EDT - 1 year ago

RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption

RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights

Apr 10, 2025, 7:48 AM EDT - 1 year ago

RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights

RedHill Biopharma to submit UK MAA for Talicia

2025-03-18T11:05:51.000Z - 1 year ago

RedHill Biopharma to submit UK MAA for Talicia

RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation

Mar 18, 2025, 7:00 AM EDT - 1 year ago

RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation

RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results

Mar 12, 2025, 7:00 AM EDT - 1 year ago

RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results

RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum

Feb 27, 2025, 7:00 AM EST - 1 year ago

RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum

RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties

Feb 25, 2025, 7:00 AM EST - 1 year ago

RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties

RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer

Feb 4, 2025, 7:00 AM EST - 1 year ago

RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer

RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published

Jan 21, 2025, 7:00 AM EST - 1 year ago

RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published

Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development

Dec 10, 2024, 7:00 AM EST - 1 year ago

Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development

RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court

Dec 2, 2024, 7:00 AM EST - 1 year ago

RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court

RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND

Oct 28, 2024, 7:00 AM EDT - 1 year ago

RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND

RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury

Oct 22, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury

RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment

Oct 14, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment

RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians

Oct 1, 2024, 7:00 AM EDT - 1 year ago

RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians

RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041

Sep 30, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041

RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines

Sep 9, 2024, 7:00 AM EDT - 1 year ago

RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines

RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sep 5, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality

Sep 3, 2024, 7:00 AM EDT - 1 year ago

New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality

RedHill Biopharma Announces First Half 2024 Business Highlights

Aug 29, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Announces First Half 2024 Business Highlights

RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma

Aug 26, 2024, 7:00 AM EDT - 1 year ago

RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma

Talicia® Launched in the United Arab Emirates

Aug 21, 2024, 7:00 AM EDT - 1 year ago

Talicia® Launched in the United Arab Emirates

RedHill Announces Positive Obesity and Diabetes Results with Opaganib

Aug 19, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces Positive Obesity and Diabetes Results with Opaganib

RedHill Biopharma Announces Plan to Implement ADS Ratio Change

Aug 16, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Announces Plan to Implement ADS Ratio Change

Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease

Aug 1, 2024, 7:00 AM EDT - 1 year ago

Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease

RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien

Jul 22, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien

RedHill Biopharma Terminates License Agreement for Aemcolo®

Jul 9, 2024, 8:00 AM EDT - 2 years ago

RedHill Biopharma Terminates License Agreement for Aemcolo®

RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040

Jun 3, 2024, 7:00 AM EDT - 2 years ago

RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040

RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035

May 6, 2024, 7:00 AM EDT - 2 years ago

RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035

RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study

Apr 24, 2024, 7:00 AM EDT - 2 years ago

RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study

BillionerOfKing
BillionerOfKing Apr. 30 at 7:41 PM
$RDHL Current Stock Price: $1.09
0 · Reply
Popajay
Popajay Apr. 30 at 1:53 PM
$RDHL RALEIGH, N.C. and TEL AVIV, Israel, April 30, 2026 /PRNewswire/ -- RedHill Biopharma Ltd.(RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced new in vitro testing results demonstrating RHB-204's comparability to RHB-104 in Mycobacterium avium subspecies paratuberculosis (MAP) killing efficacy. Oral RHB-204 is a next-generation optimized formulation of RedHill's RHB-104, designed for enhanced tolerability, safety profile and patient adherence, that employs a groundbreaking MAP-targeted therapeutic approach to the treatment of Crohn's disease (CD).
0 · Reply
Popajay
Popajay Apr. 30 at 1:52 PM
$RDHL Expected transferal of RHB-104's FDA pediatric orphan drug designation to RHB-204, potential for breakthrough therapy designation, fast track designation, additional regulatory exclusivity and priority review voucher. RHB-204 is patent protected through 2041, granted FDA Fast Track and Orphan Drug Designation, QIDP Designation under the GAIN Act (extending US market exclusivity to a potential total of 12 years) and EU Orphan Designation (eligibility for 10 years EU market exclusivity) for NTM disease caused by MAC5 The multibillion-dollar CD market is expected to grow from $13.6 billion in 2024 to over $19 billion in 2033 in key markets,6 presenting a significant opportunity for new FDA-approved therapies
0 · Reply
Popajay
Popajay Apr. 30 at 1:50 PM
$RDHL New RHB-204 in vitro data, from both spot and phage assays, demonstrated comparable MAP killing to RHB-1044. Importantly, MAP killing efficacy was achieved with lower doses of two of the active ingredients compared to RHB-104, indicative of potential for reduced toxicity and side effects Based on the FDA guidance on path to approval, RedHill's novel Phase 2 RHB-204 study is designed to be the first-ever adequately controlled clinical study in a specifically defined MAP-positive CD patient population - a potentially paradigm changing approach to treatment of Crohn's disease. With discussions ongoing and grant application submitted, funding for this program is planned to be non-dilutive
0 · Reply
Popajay
Popajay Apr. 30 at 1:50 PM
$RDHL RHB-2041 is a next-generation optimized formulation of RedHill's oral RHB-1042, designed for enhanced tolerability, safety profile and patient adherence, that employs a groundbreaking Mycobacterium avium subspecies paratuberculosis (MAP)-targeted therapeutic approach for Crohn's disease (CD) In its positive Phase 3 study, RHB-104 met the primary and key secondary endpoints with statistical significance, showing RHB-104 plus standard of care (SoC) to be 64% more effective than SoC alone, in treating CD compared to the placebo (standard of care only) group (p = 0.0048)3
0 · Reply
DARKP00L
DARKP00L Apr. 30 at 11:23 AM
$RDHL 07:12 on Apr. 30 2026 Redhill Biopharma Announces New In Vitro Testing Results Demonstrating RHB-204's Comparability To RHB-104 In Mycobacterium Avium Subspecies Paratuberculosis Killing Efficacy #tradeideas
0 · Reply
Patrick2343
Patrick2343 Apr. 27 at 5:03 PM
$RDHL RedHill is actively pursuing funding opportunities and partnerships to advance this potential paradigm-shifting treatment. - aka we will dilute.
0 · Reply
Balmus
Balmus Apr. 27 at 12:40 PM
$RDHL Going Concern Our consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. During the year ended December 31, 2025, our net cash used in operating activities was $9.7 million leaving a cash balance of $4.1 million. Because we do not have sufficient resources to fund our operations for the next twelve months from the date of this filing, management has substantial doubt of our ability to continue as a going concern. See "- B. Operating Results - Going Concern". https://www.marketscreener.com/news/redhill-biopharma-annual-report-for-fiscal-year-ending-2025-12-31-form-20-f-ce7f59dcd18ef223
1 · Reply
SavageJohnny
SavageJohnny Apr. 26 at 5:27 AM
$RDHL Nasdaq Compliance Issues: On April 14, 2026, the company received a formal notice from Nasdaq because its share price had closed below $1.00 for 30 consecutive business days (Feb 20 – April 2). RedHill has until October 5, 2026, to regain compliance by having the stock close at $1.00 or higher for at least 10 consecutive business days
0 · Reply
Patrick2343
Patrick2343 Apr. 23 at 7:28 PM
$RDHL I had bought some shares in the 70's sold them all today I have learned how they pump and dump this thing. When it runs up its best to unload asap before the dump it with an offering.
0 · Reply
Patrick2343
Patrick2343 Apr. 22 at 5:08 PM
$RDHL the pump an dumbs have really gotten pathetic now and nobody believes any of it. Probably why this pump only is up 3% everyone knows its just bs nonsense so they can sell more shares. Company is a total scam.
0 · Reply
Patrick2343
Patrick2343 Apr. 22 at 2:14 PM
$RDHL probably deserves a bonus for the CEO better do a new offering.
0 · Reply
therealchorris
therealchorris Apr. 22 at 12:17 PM
$RDHL Another fluff PR about Opaganib to pump the stock for RS and offering.
1 · Reply
therealchorris
therealchorris Apr. 15 at 3:48 PM
$RDHL The fact that no large pharma company scooped them up at less than $4M market cap tells how useless their patents and therapies are.
0 · Reply
therealchorris
therealchorris Apr. 15 at 3:45 PM
$RDHL Here we go again. Nasdaq should just delist this sh’t.
0 · Reply
Balmus
Balmus Apr. 14 at 12:38 PM
$RDHL RedHill Biopharma receives Nasdaq notice on minimum bid price requirement--https://m.uk.investing.com/news/sec-filings/redhill-biopharma-receives-nasdaq-notice-on-minimum-bid-price-requirement-93CH-4606702?ampMode=1
0 · Reply
tatanka9
tatanka9 Apr. 10 at 3:07 PM
$RDHL Scam!
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 2 at 3:02 PM
$RDHL RSI: 38.85, MACD: -0.0568 Vol: 0.06, MA20: 0.85, MA50: 0.98 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
1 · Reply
Patrick2343
Patrick2343 Mar. 30 at 2:23 PM
$RDHL When is the next RS for this ponzi scheme? This is nothing but a grift for them to pay themselves.
0 · Reply
Momikhan
Momikhan Mar. 26 at 6:21 PM
$RDHL This stock and management must be reported as soon as possible. They are looting money so hard.
0 · Reply
Patrick2343
Patrick2343 Mar. 26 at 5:18 PM
$RDHL If you want to know whey all they do is dilute see below. Its nothign but a ponzi scheme to pay themselves. e Title Pay Exercised Year Born Mr. Dror Ben-Asher Co-Founder, Chairman & CEO 566.47k -- 1966 Mr. Razi Ingber Chief Financial Officer 349.51k -- 1984 Mr. Adi Frish Chief Corporate & Business Development Officer 322.59k -- 1970 Mr. Rick D. Scruggs Chief Commercial Officer & Director 443.74k -- 1960 Mr. Gilead Raday MPhil, MSc Chief Operating Officer 365.56k -- 1975 Dr. Mark L. Levitt M.D., Ph.D. Chief Scientific Officer -- -- -- Ms. Alexandra Okmian Senior Business Development & Investor Relations Manager -- -- -- Dr. Reza Fathi Ph.D. Senior Vice President of Research & Development 299.29k -- 1955 Mr. Guy Goldberg J.D. Chief Business Officer 338.13k
0 · Reply